{"classes":[{"categories":[{"measurements":[{"comment":"not reached","groupId":"OG000","lowerLimit":"19.6","upperLimit":"NA","value":"33.6"},{"groupId":"OG001","lowerLimit":"18.6","upperLimit":"54.0","value":"31.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"48"}],"units":"Participants"}],"description":"From date of registration to date of first documentation of progression or death due to any cause.\n\nPer the International Uniform Response Criteria for Multiple Myeloma, progression is defined as \\>=1 of Serum M protein increase \\>= 25% from lowest response level, with an absolute increase of \\>= 0.5g/dL; Urine M protein increase \\>= 25% from lowest response level, with an absolute increase of \\>= 200 mg/24 hrs; If participant had serum M protein \\<1 g/dL, urine M protein \\<200 mg/24 hrs, and an involved serum free light chain level \\>= 10mg/dL at baseline: \\>= 25% increase in the difference between involved and uninvolved serum free light chain level with an absolute increase of \\>= 10 mg/dL; Bone marrow plasma cell % increase =25% from baseline with the absolute plasma cell % \\>=10%; New bone lesions or soft tissue plasmocytomas, or definite increase in size of existing bone lesions or soft tissue plasmocytomas; Development of hypercalcemia that can be attributed solely to multiple myeloma","dispersionType":"95% Confidence Interval","groups":[{"description":"INDUCTION: Participants receive bortezomib SC or IV on days 1, 4, 8, and 11; lenalidomide PO QD on days 1-14; and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity (participants who received a course of chemotherapy prior to registration will begin protocol treatment with course 2 and receive a total of 7 courses of protocol therapy).\n\nMAINTENANCE: Participants receive bortezomib SC or IV on days 1, 8, and 15; lenalidomide PO QD on days 1-21; and dexamethasone PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nBortezomib: Given SC or IV\n\nDexamethasone: Given PO or IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO","id":"OG000","title":"Arm I (Bortezomib, Lenalidomide, Dexamethasone)"},{"description":"INDUCTION: Participants receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Participants also receive elotuzumab IV on days 1, 8, and 15 of courses 1 and 2 and on days 1 and 11 of courses 3-8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE:Participants receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Participants also receive elotuzumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nBortezomib: Given SC or IV\n\nDexamethasone: Given PO or IV\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO","id":"OG001","title":"Arm II (Bortezomib, Lenalidomide, Dexamethasone, Elotuzumab)"}],"paramType":"MEDIAN","populationDescription":"Eligible and analyzable participants","reportingStatus":"POSTED","timeFrame":"Up to 6 years post registration","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"months"}